April 06, 2026 —
Affinia Therapeutics has received clinical trial application (CTA) approval from Health Canada for AFTX-201, an investigational AAV-based gene therapy for the treatment of BAG3-associated dilated cardiomyopathy (DCM), a severe inherited cardiac condition with high mortality and limited treatment options.
AFTX-201 is designed to deliver a full-length, fully human BAG3 transgene using a proprietary AAV capsid engineered for efficient cardiac targeting. According to the company, this capsid enables therapeutic delivery at doses approximately 5–10 times lower than those typically required with conventional capsids such as AAV9 or AAVrh74, potentially improving safety and manufacturability. The therapy is administered as a one-time intravenous infusion and aims to restore normal BAG3 protein expression, addressing the underlying genetic cause of disease.
The therapy will be evaluated in the Phase 1/2 UPBEAT clinical trial, a multicenter, open-label study designed to assess safety, tolerability, pharmacodynamics, and preliminary efficacy in adults with genetically confirmed BAG3 DCM. Participants will receive a single dose of AFTX-201, with primary endpoints focused on safety over 52 weeks and secondary endpoints evaluating biological activity and early signs of clinical benefit.
Preclinical data have demonstrated that AFTX-201 can restore BAG3 protein levels in the heart and normalize cardiac function in animal models, supporting its advancement into clinical testing. The CTA approval in Canada follows recent regulatory progress in the United States, where the U.S. Food and Drug Administration accepted the company’s investigational new drug application and granted Fast Track designation. Additionally, the European Medicines Agency has awarded Orphan Drug designation for the program.
BAG3-associated dilated cardiomyopathy affects tens of thousands of patients globally and is characterized by progressive heart failure, often leading to transplantation. There are currently no therapies that directly target the genetic root cause of the disease. The advancement of AFTX-201 into clinical trials represents a significant step toward a potential disease-modifying treatment for this underserved patient population.
